1 of 1

Michael L. Ferm1, Daniel J. DeSalvo1, Chuan Zhou2, Miranda C. Bradford2, Faisal S. Malik2, Maeve B. O’Donnell2, Catherine Pihoker2, Abby R. Rosenberg3, Joyce P. Yi-Frazier2,3, Marisa E. Hilliard1

Behavioral Interventions and Glycemic Outcomes: Longitudinal CGM Analysis in Teens with Diabetes Distress in the PRISM-T1D Trial

Introduction

Methods

  • 2-site (Houston & Seattle), 1:1 RCT of PRISM vs. Usual Care
  • Teens (13-18 yrs) with elevated diabetes distress
    • Problem Areas in Diabetes – Teen screener score ≥30
  • Analyzed subsample of CGM users (n = 104/172)
  • Wilcoxon rank sum tests compared within-person CGM metrics between groups between baseline, 6, and 12 months

Results

  • Table 1 summarizes CGM user characteristics
  • Table 2 & Figure 1 present within-person CGM metrics from baseline to 6 months and baseline to 12 months
  • Time in range (TIR) declined by an average of 5.88% from baseline to 12 months in the usual care group compared to 1.23% in the PRISM group, while time in level 2 hyperglycemia increased by 4.93% in the usual care group and 0.06% in the PRISM group over the same period.
  • No within-person differences reached statistical significance

Conclusions

1Baylor College of Medicine and Texas Children’s Hospital; Houston, TX

2Seattle Children’s Research Institute; Seattle, WA

3Dana-Farber Cancer Institute, Harvard Medical School; Boston, MA

Study Protocol

Presenting Author: M.L. Ferm, MD - ferm@bcm.edu

Funding from NIDDK: 1R01DK121224, 3R01DK119246-03S1, 1K26DK138332

Clinically significant Time in Range difference after behavioral intervention in teens with diabetes distress

  • The Promoting Resilience in Stress Management (PRISM) -T1D trial involved a brief, behavioral intervention to help teens with T1D and elevated diabetes distress develop resilience resources and skills
  • In this exploratory analysis, less decline in TIR at a clinically significant level in the PRISM group suggests potential glycemic benefit from a resilience-building intervention
  • Additional therapeutic components may be needed to enhance the impact of psychosocial intervention on glycemic metrics
  • PRISM benefitted psychosocial outcomes, but not HbA1c
  • Aim: Explore PRISM impact on CGM metrics, given greater glycemic specificity

Tables & Figures

Figure 1. Graphic representation of mean within-person difference in CGM ranges from baseline to 6 months (A) and baseline to 12 months (B). TAR, Time Above Range; TIR, Time In Range; TBR, Time Below Range; Glucose units: mg/dL.

B.

A.

1 hour TIR difference